ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Sebetralstat (Ekterly)

Ekterly is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. 

Orphan
CHMP opinion 24 Jul 2025 → EU licence 17 Sept 2025 · Kalvista Pharmaceuticals (Ireland) Limited

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.